EFFICACY OF EVEROLIMUS IN COMBINATION WITH LETROZOLE, MEGESTROL ACETATE, AND PACLITAXEL FOR RECURRENT ENDOMETRIAL CANCER
Received: 2025-05-14 20:52:32
Published: 2025-06-28
Abstract
Introduction. Everolimus, an mTOR inhibitor, has already demonstrated efficacy in endometrial cancer, but experience with its use in Uzbekistan is limited. Resistance to standard therapy often develops in recurrent/metastatic endometrial carcinoma, underscoring the need for novel treatment regimens. Objective. To assess the efficacy and safety of everolimus‐based combination therapies in this patient population. Materials and methods. This retrospective, single‐center study (May 2022 – June 2024) enrolled 44 patients who had previously received platinum and paclitaxel. In Group 1 (n = 14), patients received everolimus 10 mg daily in combination with letrozole, megestrol acetate, or paclitaxel; Group 2 (control, n = 30) received the same regimens without everolimus. Tumor response was evaluated every eight weeks using RECIST v1.1, and toxicity was graded according to CTCAE v5.0. Results. The objective response rate was 28.6% in the everolimus group versus 13.3% in controls (p = 0.18), while the disease control rate was 78.6% versus 50.0% (p = 0.047). Median time to progression (TTP) increased to 6.2 months (HR 0.46; p = 0.011), and median overall survival (OS) to 28.0 months (HR 0.55; p = 0.032). Grade 3–4 stomatitis and hyperglycemia each occurred in 14% of patients; only one patient discontinued therapy due to toxicity. Conclusion. The addition of everolimus significantly improved disease control and prolonged TTP and OS with acceptable safety, supporting its use in this setting and corroborating existing phase II data.
List of references
-
Bogani G., Chiappa V., Lorusso D., Raspagliesi F. Treatment of Recurrent Endometrial Carcinoma: Progress Toward a More Personalized Approach. Journal of Clinical Oncology. 2015. 33(30), 3516. https://doi.org/10.1200/JCO.2015.61.4636
-
Pham M., Joseph D., Fellman B. et al. O035/#427 Exploring the role of moelecular aberrations in predicting response to everolimus in the treatment of endometrial cancer. Int J Gynecol Cancer. 2022;32(Suppl 3):A1–A274 A21. https://doi.org/10.1136/ijgc-2022-igcs.37
-
Ray-Coquard I., Favier L., Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. British Journal of Cancer. 2013, 108(9), 1771–1777. https://doi.org/10.1038/BJC.2013.183
-
Ring K., Celestino J., Yates M. et al. Is Rad/let/met More Than Just a Catchy Name? A Preclinical Evaluation of Everolimus, Letrozole, and Metformin in Recurrent Endometrial Cancer. Gynecologic Oncology. 2014, 134 (2), 429-430. https://doi.org/10.1016/j.ygyno.2014.04.018
-
Slomovitz B.M., Jiang Y., Yates M.S. et al. Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. Journal of Clinical Oncology. 2015, 33(8), 930–936. https://doi.org/10.1200/JCO.2014.58.3401
-
Slomovitz B.M., Brown J., Johnston T.A. et al. Coleman A Phase Ii Study of Everolimus and Letrozole in Patients with Recurrent Endometrial Carcinoma. Journal of Clinical Oncology. 2011, 29:15_suppl, 5012-5012. https://doi.org/10.1200/jco.2011.29.15_suppl.5012
-
Soliman P.T., Westin Sh.N., Iglesias D.A. et al. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clinical Cancer Research. 2020; 26(3), 581–587. https://doi.org/10.1158/1078-0432.CCR-19-0471
About the Authors
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
